In this article, we will look at the 10 Best Stocks to Buy for the Next Decade.
A 10-year investing horizon shifts the conversation away from short-term noise toward something more durable: which businesses can keep growing, adapting, and compounding through different market environments. Franklin Templeton says markets are “transitioning from a narrow, liquidity-driven regime to one shaped by fundamentals, innovation, and active management,” which is another way of saying the next stretch may reward business quality more than simple momentum. For long-term investors, this shift is worth watching.
The institutional case for owning quality stocks over the long run is clear. Fidelity points investors toward “best-in-class companies” with “deep competitive moats” and says stocks with “long-term growth potential” can “compound earnings over time.” J.P. Morgan Asset Management adds that “High quality stocks are now priced at a discount,” and says the quality factor in U.S. markets is “more attractive than ever” outside unusually dislocated periods. Franklin Templeton makes the same argument from a longer-cycle perspective, emphasizing “high-quality growth companies with durable competitive advantages” and a process aimed at “sustainable alpha across cycles.” The best decade-long ideas are usually not the flashiest ones, but the companies with staying power, pricing power, and room to keep building value.
Against this backdrop, we will look at the 10 Best Stocks to Buy for the Next Decade.
Our Methodology
We used the Finviz screener to identify high-quality stocks that exhibited over 20% EPS annual growth over the last 5 years and are forecasted to grow EPS annually by over 20% in the next 5 years. We then limited our final selection to companies that have recently reported noteworthy developments likely to impact investor sentiment. These stocks are also popular among analysts and elite hedge funds.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 498.7% since May 2014, beating its benchmark by 303 percentage points (see more details here).
10. Eli Lilly and Company (NYSE:LLY)
On April 15, 2026, Eli Lilly and Company (NYSE:LLY) disclosed that the U.S. FDA had requested additional data related to potential liver injury associated with its newly approved obesity pill, along with post-marketing studies on cardiovascular risks and gastric emptying, according to a Reuters report. The agency also required a lactation study as part of its ongoing safety monitoring under the drug’s priority review approval. A Lilly spokesperson said there were no indications of liver damage in late-stage trials, adding that “The FDA approved Foundayo based on its review of data from the ATTAIN clinical program,” with post-approval requirements consistent with standard safety evaluation practices.
On April 12, 2026, Lilly reported topline results from the Phase 3 BRUIN CLL-322 trial evaluating Jaypirca, a non-covalent Bruton tyrosine kinase inhibitor, in combination with venetoclax and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma. The study met its primary endpoint, showing a statistically significant and clinically meaningful improvement in progression-free survival versus venetoclax and rituximab alone, with results consistent across key subgroups, including patients previously treated with a covalent BTK inhibitor. Overall survival data were not yet mature but trended in favor of the combination regimen, while the safety profile remained consistent with known profiles, and discontinuation rates were low across both arms. Lilly plans to present detailed data at a medical conference and submit findings to regulators for potential label expansion later this year.
On April 9, 2026, Morgan Stanley raised its price target on Eli Lilly to $1,327 from $1,313 and maintained an Overweight rating, reflecting model updates across its biopharma coverage ahead of Q1 earnings.
Eli Lilly and Company (NYSE:LLY) develops and markets pharmaceutical products globally.
9. Amphenol Corporation (NYSE:APH)
On April 14, 2026, UBS lowered its price target on Amphenol Corporation (NYSE:APH) to $170 from $174 and maintained a Buy rating. The firm said valuations have become more reasonable after turning cautious following Q4 results and 2026 guidance, which had highlighted limited upside and reliance on multiple expansion. UBS added that while demand concerns and potential production cuts could weigh on sentiment and near-term margins may face pressure from inflation, expectations have already reset lower, suggesting that even modest estimate cuts or reaffirmed guidance could be received positively by investors.
On April 8, 2026, Citi lowered its price target on Amphenol to $170 from $180 and kept a Buy rating. The firm noted that copper interconnect names have seen multiple compressions as the shift toward optical interconnect accelerates, but said the recent selloff in Amphenol presents an “attractive setup,” supported by constructive data center demand commentary during Q1.
Earlier, following its acquisition of the Connectivity and Cable Solutions business from Vistance Networks, Amphenol launched an open offer to acquire up to 1,196,000 equity shares of ADC India Communications, representing 26.0% of the company’s voting share capital, from public shareholders. The tendering period runs from April 2 to April 17, 2026, in accordance with SEBI regulations. The offer price is INR 1,233.59 per share, implying a total cash consideration of approximately INR 1.48B, assuming full acceptance. The open offer, which is not subject to a minimum acceptance threshold, was triggered by Amphenol’s indirect acquisition of control of the target company under a purchase agreement dated August 3, 2025, and follows the completion of the CCS acquisition, after which ADC India became an indirect majority-owned subsidiary.
Amphenol Corporation (NYSE:APH) manufactures connectors and interconnect systems globally.
